Novartis Reports Tumors Possibly Linked to Zolgensma Treatment
Novartis has acknowledged seven previously unknown instances of tumors found in children treated with its spinal muscular atrophy therapy, Zolgensma. This development has raised concerns among families, physicians, and patient advocacy groups. The cases are currently regarded as a potential safety signal and were publicized by an advocacy group and on a Facebook page after…









